PROGRAM MENU
Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. The THSNA 2020 program will include on demand access to recorded talks covering four educational tracks as well as live panel discussion sessions, a nursing workshop, digital posters, corporate symposia, and a virtual exhibit hall with commercial booths.

Note that all timea are listed in Eastern Daylight Time (EDT) and any aspect of this program is subject to change.

  Tue - Oct 27      Wed - Oct 28      Thu - Oct 29      Fri - Oct 30   

FRIDAY, OCTOBER 30

10:00 - 11:30 AM
PLENARY SESSION
PLENARY 4: WERE ALL IN THIS FIGHT TOGETHER: PERSPECTIVES ON COVID-19
Chair/Organizer: Anne Rose, Cathy Hayward,

Over the past year, the world has battled the global pandemic caused by the virus COVID-19. Experts in this closing Plenary will cover broad and unique perspectives on COVID-19 infection and what has been learned from fighting this infection in North America and beyond. The session will also address some fascinating aspects of COVID-19, including how this infection can affect children and the importance of recognizing and addressing the thrombotic complications of COVID-19.



OVERVIEW OF COVID-19: A BROAD PERSPECTIVE ON WHAT WE'VE BEEN THROUGH IN NORTH AMERICA AND BEYOND
Zain Chagla. McMaster University


COVID-19 INFECTION IN CHILDREN
Jennifer Davila. Children's Hospital at Montefiore


COVID-19 AND THROMBOSIS
Rachel Rasovsky. Massachusetts General Hospital

12:15 - 1:15 PM
SATELLITE SYMPOSIUM
CORPORATE LUNCH SYMPOSIM: FINAL RESULTS FROM THE NUWIQ PUP STUDY: INHIBITOR RATES & BEYOND

Sponsored By: Octapharma

Dr. Ellis Neufeld will present final data from the NuProtect study. Octapharma USA is the sponsor of this program. NuProtect is a prospective, multinational, open-label, phase III study to assess the immunogenicity, efficacy and safety of NUWIQ Antihemophilic Factor (Recombinant), a human cell line-derived rFVIII, in previously untreated patients (PUPs) with severe hemophilia A. NuProtect is the largest prospective study of a single FVIII product in PUPs with hemophilia A, conducted in 105 PUPs followed for up to 100 exposure days. Final results showed a cumulative incidence of high-titer inhibitors of 17. 6%. Dr. Neufeld will discuss these results in the context of the SIPPET study, in which the cumulative incidence of high-titer inhibitors was 28. 4% in patients treated with rFVIII products derived from hamster cell lines and 18. 6% in those treated with plasma-derived FVIII. In addition, new data on efficacy and implications of FVIII gene mutation analysis will be shared. The completion of NuProtect represents a major clinical milestone for NUWIQ and the hemophilia community.



CORPORATE LUNCH SYMPOSIUM: INVESTIGATIONAL AAV GENE THERAPIES: PRACTICAL SITE CONSIDERATIONS

Sponsored By: BioMarin

Join us to understand what makes AAV gene therapy research and its potential practical applications different from other treatment types. Dr. Guy Young will discuss the technology behind the adeno-associated virus platform being investigated and also the important questions providers of myriad specialties and institutions may have as they prepare for what could be a very different journey from consideration and eligibility, to practice, to short and longer-term post-procedure follow-up. A live Q&A session with Dr. Guy Young will be held after to answer any questions.


2:00 - 3:30 PM
HEMOSTASIS / BASIC SCIENCE
ADVANCES IN UNDERSTANDING BLEEDING DISORDERS
Chair/Organizer: Julie Jaffray, Roona Sinha


FVIII AND ITS ROLE AS THE GENETIC BASIS OF HEMOPHILIA
Chris Doering.


MODELING IMMUNE-MEDIATED THROMBOCYTOPENIA: INSIGHTS ON MECHANISMS
Heyu Ni. University of Toronto / Canadian Blood Services Centre for Innovation


GENOTYPE/PHENOTYPE DISCREPANCIES IN RARE BLEEDING DISORDERS
Diane Nugent. CHOC Childrens Hospital/UC Irvine and Center for Inherited Blood Disorders

2:00 - 3:30 PM
THROMBOSIS
ANTICOAGULATION STEWARDSHIP
Chair/Organizer: Stacy Ellsworth, Leslie Lake


THE FUTURE OF ANTICOAGULATION CLINICS AND ROLE OF CLINICIANS
Arthur Allen. VA Salt Lake City Health Care System


ESTABLISHING AN ANTICOAGULATION STEWARDSHIP PROGRAM (REVIEW OF FDA/TJC STANDARDS AND AC FORUM GUIDANCE)
Scott Kaatz. Henry Ford Hospital


ANTICOAGULATION STEWARDSHIP PROGRAMS (EXAMPLES OF EXCELLENCE)
Anne Rose. UW Health

2:00 - 3:30 PM
LABORATORY
UPDATE ON LABORATORY TESTING FOR ACQUIRED DISORDERS
Chair/Organizer: Joyce Rogers, Dot Adcock


UPDATE ON TESTING FOR AUTOANTIBODIES IN ACQUIRED HEMOPHILIA
Ken Friedman. Versiti - Bloodcenter of Wisconsin


LABORATORY EVALUATION OF ACQUIRED VON WILLEBRAND DISEASE
William Nichols. Mayo Clininc - Rochester, MN


LABORATORY APPROACH TO MONITORING COAGULATION DURING LIFE SUPPORT
Oksana Volod . Cedars Sinai Medical Center